Literature DB >> 18718966

Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1).

Paul Christian Baier1, Sara Lena Weinhold, Verena Huth, Birgit Gottwald, Roman Ferstl, Dunja Hinze-Selch.   

Abstract

Until recently, olfactory dysfunction was an unknown feature of narcolepsy. Orexin A, also called hypocretin-1, is abnormally decreased or undetectable in the cerebrospinal fluid of narcoleptic patients with cataplexies. As hypothalamic orexin-containing neurons project throughout the entire olfactory pathway, from the olfactory mucosa to the olfactory cortex, disturbed orexinergic transmission may crucially be involved in impaired olfactory performance of narcolepsy patients. In our study we analysed the olfactory performance (threshold, discrimination, identification and sum score of these measurements, the TDI score) of narcoleptic patients with cataplexies (n = 10) and of age-, gender-, BMI- and smoker/non-smoker-matched healthy controls (n = 10). We then in a double-blind, randomized, placebo-controlled cross-over design applied orexin A intranasally to seven of the patients and measured 2-phenyl-ethyl alcohol (PEA) single-staircase odour detection thresholds. Compared to the controls, patients showed significantly lower scores for olfactory threshold (patients: median 8.0, range 4.0-10.5; controls: median 9.4, range 7.5-13.3; P < 0.05), discrimination (patients: median 12.5, range 10-15; controls: median 15.0, range 12-16; P < 0.005), identification (patients: median 13.0, range 10-16; controls: median 14.0, range 13-16; P < 0.05) and TDI score (patients: median 33.4, range 30-36; controls: median 38.4, range 35-43; P < 0.0001). In all patients, the PEA olfactory threshold score increased after administration of orexin A (median 11.5, range 6.5-13.25) compared to placebo (median 7.75, range 6.25-11.25; P < 0.05). Our results support the hypothesis that mild olfactory dysfunction is an intrinsic symptom of narcolepsy with cataplexies. The observation that intranasal orexin A restores olfactory function is in favour of this hypothesis. Furthermore, our data support that the pathophysiological mechanism underlying olfactory dysfunction in narcolepsy is the lack of CNS orexin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718966     DOI: 10.1093/brain/awn193

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  14 in total

Review 1.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

2.  Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression.

Authors:  Clarissa D Staton; Jazmine D W Yaeger; Delan Khalid; Fadi Haroun; Belissa S Fernandez; Jessica S Fernandez; Bali K Summers; Tangi R Summers; Monica Sathyanesan; Samuel S Newton; Cliff H Summers
Journal:  Neuropharmacology       Date:  2018-09-18       Impact factor: 5.250

Review 3.  Olfaction under metabolic influences.

Authors:  Brigitte Palouzier-Paulignan; Marie-Christine Lacroix; Pascaline Aimé; Christine Baly; Monique Caillol; Patrice Congar; A Karyn Julliard; Kristal Tucker; Debra Ann Fadool
Journal:  Chem Senses       Date:  2012-07-25       Impact factor: 3.160

Review 4.  Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.

Authors:  Coleman B Calva; Jim R Fadel
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

5.  Human hypocretin-deficient narcolepsy - aberrant food choice due to impaired taste?

Authors:  Giselle de Martin Truzzi; Renata Carvalho Cremaschi; Fernando Morgadinho Coelho
Journal:  Sleep Sci       Date:  2017 Apr-Jun

6.  Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy.

Authors:  Thomas C Thannickal; Robert Nienhuis; Jerome M Siegel
Journal:  Sleep       Date:  2009-08       Impact factor: 5.849

Review 7.  Intranasal insulin and orexins to treat age-related cognitive decline.

Authors:  Jennifer M Erichsen; Coleman B Calva; Lawrence P Reagan; Jim R Fadel
Journal:  Physiol Behav       Date:  2021-02-21

Review 8.  Unmet needs of patients with narcolepsy: perspectives on emerging treatment options.

Authors:  Dariusz R Wozniak; Timothy G Quinnell
Journal:  Nat Sci Sleep       Date:  2015-05-22

Review 9.  Cataplexy--clinical aspects, pathophysiology and management strategy.

Authors:  Yves Dauvilliers; Jerry M Siegel; Regis Lopez; Zoltan A Torontali; John H Peever
Journal:  Nat Rev Neurol       Date:  2014-06-03       Impact factor: 42.937

Review 10.  Intranasal treatment of central nervous system dysfunction in humans.

Authors:  Colin D Chapman; William H Frey; Suzanne Craft; Lusine Danielyan; Manfred Hallschmid; Helgi B Schiöth; Christian Benedict
Journal:  Pharm Res       Date:  2012-11-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.